Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNR Burning Rock Biotech	$4.70 +2.0%	$3.40	$2.18 ▼ $7.90	$49.61M	0.75	23,751 shs	11,904 shs
CDNA CareDx	$11.91 +0.8%	$18.23	$10.96 ▼ $34.84	$657.59M	2.19	1.01 million shs	5.72 million shs
EKTAY Elekta	$4.95 +1.2%	$5.11	$4.36 ▼ $7.13	$1.88B	1.2	4,775 shs	5,910 shs
NVTA Invitae	$0.00	$0.00	$0.02 ▼ $0.02	$80K	1.59	23.72 million shs	75 shs
VCYT Veracyte	$23.51 -2.9%	$27.15	$19.73 ▼ $47.32	$1.90B	2.07	920,378 shs	1.61 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNR Burning Rock Biotech	+1.10%	+17.45%	+32.47%	+64.64%	-29.40%
CDNA CareDx	-38.49%	-42.75%	-39.50%	-32.97%	-35.46%
EKTAY Elekta	0.00%	-4.35%	-1.41%	-0.81%	-22.13%
NVTA Invitae	0.00%	0.00%	0.00%	0.00%	-25.00%
VCYT Veracyte	-3.77%	-11.99%	-9.49%	-22.22%	-4.19%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BNR Burning Rock Biotech	1.123 of 5 stars	0.0	4.0	0.0	0.0	2.1	1.7	0.6
CDNA CareDx	4.1965 of 5 stars	3.3	1.0	0.0	4.2	3.0	0.8	1.9
EKTAY Elekta	1.4333 of 5 stars	0.0	3.0	1.7	0.0	0.0	1.7	1.9
NVTA Invitae	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VCYT Veracyte	3.5839 of 5 stars	3.4	1.0	0.0	4.3	2.7	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNR Burning Rock Biotech	0.00	N/A	N/A	N/A
CDNA CareDx	2.67	Moderate Buy	$29.33	146.29% Upside
EKTAY Elekta	2.00	Hold	N/A	N/A
NVTA Invitae	0.00	N/A	N/A	N/A
VCYT Veracyte	2.70	Moderate Buy	$40.90	73.97% Upside

Current Analyst Ratings Breakdown

Latest EKTAY, BNR, CDNA, VCYT, and NVTA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/18/2025	CDNA CareDx	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $26.00
6/3/2025	EKTAY Elekta	Danske Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold
5/8/2025	VCYT Veracyte	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$49.00 ➝ $42.00
5/8/2025	VCYT Veracyte	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$51.00 ➝ $41.00
5/5/2025	CDNA CareDx	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$40.00 ➝ $40.00
5/5/2025	CDNA CareDx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$25.00 ➝ $25.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNR Burning Rock Biotech	$70.67M	0.72	N/A	N/A	$7.39 per share	0.64
CDNA CareDx	$333.79M	1.99	$1.37 per share	8.69	$7.06 per share	1.69
EKTAY Elekta	$1.71B	1.11	$0.62 per share	7.99	$2.19 per share	2.26
NVTA Invitae	$481.58M	0.00	N/A	N/A	$0.42 per share	0.00
VCYT Veracyte	$445.76M	4.13	$1.01 per share	23.36	$15.17 per share	1.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNR Burning Rock Biotech	-$47.49M	-$1.89	N/A	∞	N/A	-45.41%	-38.33%	-25.34%	8/28/2025 (Estimated)
CDNA CareDx	$52.55M	$1.15	10.36	N/A	N/A	19.79%	21.16%	14.25%	7/30/2025 (Estimated)
EKTAY Elekta	$22.37M	$0.05	16.86	11.51	N/A	1.15%	11.55%	3.75%	8/27/2025 (Estimated)
NVTA Invitae	-$3.11B	-$5.38	N/A	N/A	N/A	-299.14%	-6,100.71%	-19.68%	N/A
VCYT Veracyte	$24.14M	$0.41	57.34	32.65	N/A	7.13%	6.14%	5.60%	8/6/2025 (Estimated)

Latest EKTAY, BNR, CDNA, VCYT, and NVTA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	VCYT Veracyte	$0.31	N/A	N/A	N/A	$120.90 million	N/A
7/30/2025	Q2 2025	CDNA CareDx	$0.12	N/A	N/A	N/A	$90.72 million	N/A
6/6/2025	Q1 2025	BNR Burning Rock Biotech	N/A	-$0.17	N/A	-$0.17	N/A	$18.34 million
5/28/2025	Q4 2025	EKTAY Elekta	$0.13	$0.11	-$0.02	-$0.10	$507.19 million	$503.22 million
4/30/2025	Q1 2025	CDNA CareDx	$0.06	$0.09	+$0.03	-$0.19	$84.56 million	$84.69 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNR Burning Rock Biotech	N/A	N/A	N/A	N/A	N/A
CDNA CareDx	N/A	N/A	N/A	N/A	N/A
EKTAY Elekta	$0.12	2.42%	N/A	240.00%	N/A
NVTA Invitae	N/A	N/A	N/A	N/A	N/A
VCYT Veracyte	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNR Burning Rock Biotech	N/A	3.02	2.76
CDNA CareDx	N/A	4.11	3.84
EKTAY Elekta	0.70	1.09	0.86
NVTA Invitae	N/A	2.39	2.25
VCYT Veracyte	N/A	5.10	4.78

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNR Burning Rock Biotech	30.03%
CDNA CareDx	N/A
EKTAY Elekta	N/A
NVTA Invitae	61.28%
VCYT Veracyte	N/A

Insider Ownership

Company	Insider Ownership
BNR Burning Rock Biotech	30.30%
CDNA CareDx	4.40%
EKTAY Elekta	41.28%
NVTA Invitae	0.74%
VCYT Veracyte	1.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNR Burning Rock Biotech	1,390	10.76 million	7.50 million	Not Optionable
CDNA CareDx	740	55.68 million	53.23 million	Optionable
EKTAY Elekta	4,718	383.57 million	225.23 million	Not Optionable
NVTA Invitae	1,700	267.01 million	284.37 million	Optionable
VCYT Veracyte	790	78.32 million	77.22 million	Optionable

EKTAY, BNR, CDNA, VCYT, and NVTA Headlines

Recent News About These Companies

Veracyte Inc (VCYT) Stock Price Down 4.21% on Jul 18

July 18 at 1:43 PM | gurufocus.com

Veracyte, Inc. (NASDAQ:VCYT) Given Consensus Rating of "Moderate Buy" by Brokerages

July 18 at 2:41 AM | marketbeat.com

Veracyte to Release Second Quarter 2025 Financial Results on August 6, 2025

July 17 at 5:30 PM | businesswire.com

Segall Bryant & Hamill LLC Has $13.90 Million Stake in Veracyte, Inc. (NASDAQ:VCYT)

July 17 at 6:51 AM | marketbeat.com

Should You Continue to Hold Veracyte Stock in Your Portfolio Now?

July 16 at 9:41 AM | zacks.com

New York State Common Retirement Fund Sells 118,642 Shares of Veracyte, Inc. (NASDAQ:VCYT)

July 16 at 4:33 AM | marketbeat.com

Rice Hall James & Associates LLC Acquires 19,843 Shares of Veracyte, Inc. (NASDAQ:VCYT)

July 15 at 5:45 AM | marketbeat.com

Veracyte, Inc. (NASDAQ:VCYT) Shares Sold by Teacher Retirement System of Texas

July 14, 2025 | marketbeat.com

Veracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025 - Morningstar

July 10, 2025 | morningstar.comM

Veracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025

July 9, 2025 | tmcnet.com

Wealth Enhancement Advisory Services LLC Grows Holdings in Veracyte, Inc. (NASDAQ:VCYT)

July 6, 2025 | marketbeat.com

Veracyte, Inc. (VCYT) - Yahoo Finance

July 3, 2025 | finance.yahoo.com

Veracyte, Inc. (NASDAQ:VCYT) Shares Sold by Sumitomo Mitsui Trust Group Inc.

July 1, 2025 | marketbeat.com

Wall Street Zen Downgrades Veracyte (NASDAQ:VCYT) to Hold

June 28, 2025 | marketbeat.com

AMI Asset Management Corp Has $1.44 Million Stock Holdings in Veracyte, Inc. (NASDAQ:VCYT)

June 26, 2025 | marketbeat.com

Veracyte, Inc. (NASDAQ:VCYT) Receives Average Rating of "Moderate Buy" from Analysts

June 23, 2025 | marketbeat.com

Veracyte (NASDAQ:VCYT) shareholders have earned a 19% return over the last year

June 20, 2025 | finance.yahoo.com

GAMMA Investing LLC Purchases 18,840 Shares of Veracyte, Inc. (NASDAQ:VCYT)

June 19, 2025 | marketbeat.com

Cathie Wood’s ARK buys BWX stock, sells Adaptive Biotech

June 18, 2025 | investing.com

Veracyte (VCYT) Fell Despite Reporting Revenue Growth and Improved Profitability

June 9, 2025 | msn.com

Cathie Wood's Ark Invest Loads Up On Veracyte, Offloads 3D Systems

June 7, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EKTAY, BNR, CDNA, VCYT, and NVTA Company Descriptions

Burning Rock Biotech NASDAQ:BNR

$4.70 +0.09 (+1.95%)

Closing price 03:53 PM Eastern

Extended Trading

$4.65 -0.05 (-1.04%)

As of 06:03 PM Eastern

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.

CareDx NASDAQ:CDNA

$11.91 +0.10 (+0.85%)

Closing price 04:00 PM Eastern

Extended Trading

$11.88 -0.03 (-0.21%)

As of 07:56 PM Eastern

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Elekta OTCMKTS:EKTAY

$4.95 +0.06 (+1.23%)

As of 03:16 PM Eastern

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services. It also provides Elekta Studio, an image guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; Geneva, an applicator for cervical cancer treatment; veterinary radiation therapy products; and Elekta Kaiku for personalized cancer care. In addition, the company offers stereotactic radiosurgery, such as Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Elekta Esprit. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System for minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.

Invitae NYSE:NVTA

Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.

Veracyte NASDAQ:VCYT

$23.51 -0.71 (-2.93%)

Closing price 04:00 PM Eastern

Extended Trading

$23.72 +0.22 (+0.91%)

As of 07:57 PM Eastern

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time